MX2019004574A - Forma cristalina de (1r,2r)-2-[4-(3-metil-1h-pirazol-5-il)benzoil- n-(4-oxo-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-3-il)ciclohexan ocarboxamida. - Google Patents

Forma cristalina de (1r,2r)-2-[4-(3-metil-1h-pirazol-5-il)benzoil- n-(4-oxo-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-3-il)ciclohexan ocarboxamida.

Info

Publication number
MX2019004574A
MX2019004574A MX2019004574A MX2019004574A MX2019004574A MX 2019004574 A MX2019004574 A MX 2019004574A MX 2019004574 A MX2019004574 A MX 2019004574A MX 2019004574 A MX2019004574 A MX 2019004574A MX 2019004574 A MX2019004574 A MX 2019004574A
Authority
MX
Mexico
Prior art keywords
tetrahydropyrazolo
pyrazol
oxo
crystalline form
exanecarboxamide
Prior art date
Application number
MX2019004574A
Other languages
English (en)
Inventor
Matilda Angelica Pettersen Anna
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2019004574A publication Critical patent/MX2019004574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/50—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma cristalina de (1R,2R)-2-[4-(3-metil-1H-pirazol-5-il)benz oil]-N-(4-oxo-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-3-il)ciclo hexanocarboxamida, composiciones farmacéuticas que la contienen y su uso en la terapia.
MX2019004574A 2016-10-28 2017-10-27 Forma cristalina de (1r,2r)-2-[4-(3-metil-1h-pirazol-5-il)benzoil- n-(4-oxo-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-3-il)ciclohexan ocarboxamida. MX2019004574A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662414109P 2016-10-28 2016-10-28
PCT/EP2017/077602 WO2018078097A1 (en) 2016-10-28 2017-10-27 Crystalline form of (1r,2r)-2-[4-(3-methy1-1h-pyrazol-5-yl)benzoyl]-n-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)cyclohexanecarboxamide

Publications (1)

Publication Number Publication Date
MX2019004574A true MX2019004574A (es) 2019-08-21

Family

ID=60387981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004574A MX2019004574A (es) 2016-10-28 2017-10-27 Forma cristalina de (1r,2r)-2-[4-(3-metil-1h-pirazol-5-il)benzoil- n-(4-oxo-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-3-il)ciclohexan ocarboxamida.

Country Status (17)

Country Link
US (1) US10689387B2 (es)
EP (1) EP3532050B1 (es)
JP (1) JP7041146B2 (es)
KR (1) KR102509478B1 (es)
CN (1) CN109890385B (es)
AU (1) AU2017348598B2 (es)
CA (1) CA3040341C (es)
CL (1) CL2019000997A1 (es)
EA (1) EA201990957A1 (es)
ES (1) ES2933178T3 (es)
IL (1) IL266031B (es)
MA (1) MA46628A (es)
MX (1) MX2019004574A (es)
MY (1) MY188809A (es)
SG (1) SG11201903414SA (es)
WO (1) WO2018078097A1 (es)
ZA (1) ZA201901093B (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP9400632A0 (en) 1993-04-29 1995-10-07 Zeneca Ltd Ether derivatives.
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20100204282A1 (en) 2007-02-05 2010-08-12 Hutchinson John H Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors
EP2207547A4 (en) 2007-10-05 2010-11-17 Amira Pharmaceuticals Inc PROTEIN INHIBITORS THAT ACTIVATE 5-LIPOXYGENASE
US7951833B2 (en) * 2008-02-04 2011-05-31 Astrazeneca Ab Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471
MX2010012814A (es) * 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
SI3292105T1 (sl) * 2015-05-04 2020-01-31 Astrazeneca Ab Derivati pirazola uporabni kot inhibitorji proteina, ki aktivira 5-lipoksigenazo (FLAP)

Also Published As

Publication number Publication date
IL266031A (en) 2019-06-30
ES2933178T3 (es) 2023-02-02
ZA201901093B (en) 2020-08-26
MY188809A (en) 2022-01-05
MA46628A (fr) 2019-09-04
EA201990957A1 (ru) 2019-09-30
JP2019537586A (ja) 2019-12-26
AU2017348598B2 (en) 2020-02-20
AU2017348598A1 (en) 2019-06-06
CA3040341A1 (en) 2018-05-03
JP7041146B2 (ja) 2022-03-23
WO2018078097A1 (en) 2018-05-03
US10689387B2 (en) 2020-06-23
US20190276460A1 (en) 2019-09-12
CN109890385B (zh) 2022-08-02
EP3532050B1 (en) 2022-10-19
CA3040341C (en) 2024-03-05
KR102509478B1 (ko) 2023-03-10
CN109890385A (zh) 2019-06-14
CL2019000997A1 (es) 2019-06-21
IL266031B (en) 2021-05-31
KR20190071757A (ko) 2019-06-24
EP3532050A1 (en) 2019-09-04
SG11201903414SA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
IL276232B2 (en) History of pyrazine, pharmaceutical compounds containing them and their use in the treatment of diseases
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
MX2018006207A (es) Compuestos heterociclicos como inmunomoduladores.
TW201613901A (en) New compounds
EP3183251A4 (en) Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
PH12016502099A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
IL252053B2 (en) Converted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
SI3107914T1 (sl) Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba
MX2018003861A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
EP3215509A4 (en) Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
AU2017261291A1 (en) Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
EP3440080A4 (en) PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
NZ732371A (en) Solid state forms of fused heteroaromatic pyrrolidinones
JO3819B1 (ar) H1- بيرازولو [4، 3-b] بيريدينات كمثبطات PDE1
TN2018000321A1 (en) 1,5-dihydr0-4h-pyrazol0[3,4-d]pyrimidin-4-0nes and 1,5-dihydr0-4h-pyrazol0[4,3-c]pyridin-4-0nes as pde1 inhibitors.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
MX2015005734A (es) Metodos de tratamiento de enfermedades hepaticas.
PH12018501019A1 (en) Diamino pyridine derivatives
MX2019004574A (es) Forma cristalina de (1r,2r)-2-[4-(3-metil-1h-pirazol-5-il)benzoil- n-(4-oxo-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-3-il)ciclohexan ocarboxamida.